Sou Hu Cai Jing·2025-10-22 11:46Core Insights - The stock of Chunli Medical (688236) closed at 26.8 yuan on October 22, 2025, down by 1.03% with a trading volume of 56,000 hands and a transaction amount of 155 million yuan [1] Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, an increase of 28.27% year-on-year [3] - The net profit attributable to shareholders was 114 million yuan, up 44.85% year-on-year [3] - The second quarter of 2025 saw a single-quarter main revenue of 258 million yuan, a year-on-year increase of 62.85% [3] - The single-quarter net profit attributable to shareholders was 56.4 million yuan, up 136.7% year-on-year [3] - The company achieved a gross margin of 67.09% and a net margin of 23.48% [3] Market Position - Chunli Medical's total market capitalization is 10.28 billion yuan, ranking 37th in the medical device industry [3] - The company has a price-to-earnings ratio (P/E) of 44.9, which is lower than the industry average of 120.11 [3] - The price-to-book ratio (P/B) stands at 3.54, slightly below the industry average of 3.79 [3] Investment Sentiment - In the last 90 days, 8 institutions rated the stock, with 7 buy ratings and 1 hold rating [4] - The average target price set by institutions over the past 90 days is 30.61 yuan [4] Capital Flow - On October 22, 2025, the net inflow of main funds was 2.1672 million yuan, accounting for 1.4% of the total transaction amount [1][2] - Retail investors had a net inflow of 350,300 yuan, representing 0.23% of the total transaction amount [1][2]